About 127,423 results

ALLMedicine™ Lung Cancer Center

Research & Reviews  41,871 results

Awareness of Tobacco-Related Diseases among Adults in Poland: A 2022 Nationwide Cross-S...
International Journal of Environmental Research and Publi... Szymański J, Ostrowska A et. al.

May 15th, 2022 - Warning about the dangers of tobacco use is a key element of tobacco control policy. The COVID-19 pandemic may impact public perception of the health risks of tobacco use. The aim of this study was to assess the level of knowledge of tobacco-relat...

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis.
Cancer Medicine; Goussault H, Gendarme S et. al.

May 15th, 2022 - Despite therapeutic advances, lung cancer remains the first cause of death from cancer. The main objective of this study was to identify risk factors associated with death within 3-months of the first hospitalization for lung cancer in France. Thi...

Trends of cancer mortality in Xi'an City, China: 2005-2020.
https://doi.org/10.1007/s00432-022-04046-6 10.3390/ijerph182111198 10.1093/ije/dyh414 10.1093/annonc/mds337 10.1002/cam4.1321 10.1007/s40292-015-0114-3 10.1177/030089160909500605 10.1093/annonc/mdm597 10.1093/annonc/mdg305 10.1158/1055-9965.EPI-04-0569 10.3322/caac.21492 10.1002/cncr.33587 10.1002/cphy.c120005 10.1016/j.annonc.2021.06.023 10.1016/j.vaccine.2010.12.085 10.1016/j.enfcli.2018.03.002 10.1002/cam4.2765 10.1016/S2214-109X(18)30488-1 10.1016/S0140-6736(13)60022-7 10.1016/S1473-3099(07)70158-5 10.7314/APJCP.2015.16.17.7401 10.1016/j.fct.2017.04.028 10.1002/cncr.10593 10.1016/S1470-2045(13)70567-9 10.1158/1055-9965.EPI-15-0134 10.1136/oemed-2011-100310 10.2174/2211738507666190122111224 10.1093/nutrit/nux012 10.5588/ijtld.19.0106 10.1080/21645515.2021.2007709 10.1093/annonc/mdw027 10.1186/s12905-021-01260-1 10.1001/jama.2013.285112 10.1053/j.gastro.2017.04.022 10.1093/oxfordjournals.epirev.a036288 10.3322/caac.20107 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z 10.1002/ajim.23093 10.1016/S0959-8049(00)00052-6 10.1007/s10552-008-9132-y 10.1056/NEJMsr1606602 10.2188/jea.JE20120217 10.3322/CA.2007.0018 10.3390/ijerph17218234 10.1007/s00705-021-04960-z 10.3390/ijerph14090967 10.1016/S1470-2045(13)70487-X 10.1002/ijc.33114 10.1007/s10549-015-3628-4 10.1183/13993003.00359-2016 10.1093/annonc/mdz051 10.1007/s10552-012-0130-8 10.1016/S0140-6736(10)61388-8 10.1002/cncr.28105 10.1002/ijc.21731 10.3322/canjclin.55.2.74 10.1080/14737140.2019.1642109 10.1002/ijc.28999 10.1093/aje/kwx166 10.1002/cac2.12197 10.3945/ajcn.111.031674 10.1093/jnci/djv319 10.1016/j.lungcan.2004.07.998 10.1186/1750-9378-7-38 10.1016/j.cgh.2014.04.009 10.1007/s10552-007-9105-6 10.7314/APJCP.2014.15.22.10021 10.20892/j.issn.2095-3941.2020.0387 10.3322/caac.21660 10.2188/jea.JE20100190 10.3322/caac.21262 10.1158/1055-9965.EPI-15-0578 10.1093/annonc/mdr135 10.1002/ijc.32014 10.1016/j.canep.2015.10.006 10.1016/S0140-6736(13)62224-2 10.1177/0300060515592901 10.1016/j.envres.2019.108748 10.3322/canjclin.54.2.78 10.1155/2012/921607 10.1001/jamanetworkopen.2019.1474 10.1056/NEJMoa1100370 10.1016/S0140-6736(18)32849-6
Journal of Cancer Research and Clinical Oncology; Chen N, Zhang XY et. al.

May 15th, 2022 - Describe and predict the malignant tumor deaths in Xi'an so as to provide evidence for the government to formulate the prevention and treatment plans. Overall malignant tumor death in Xi'an in the past 16 years was described. The multi-decrease li...

Identifying the individual metabolic abnormities from a systemic perspective using whol...
https://doi.org/10.1007/s00259-022-05832-7 10.1523/JNEUROSCI.2930-16.2016 10.15252/msb.20198982 10.1371/journal.pone.0100963 10.1016/j.neuroimage.2007.02.012 10.1093/cercor/bhn059 10.1093/brain/awr327 10.1007/s00259-020-04814-x 10.1093/brain/awaa238 10.1002/hbm.22753 10.1177/0271678X17708692 10.1038/s41598-019-39005-8 10.1007/s11548-016-1501-5 10.1002/hbm.22298 10.1093/cercor/bhx294
European Journal of Nuclear Medicine and Molecular Imaging; Sun T, Wang Z et. al.

May 15th, 2022 - Distinct physiological states arise from complex interactions among the various organs present in the human body. PET is a non-invasive modality with numerous successful applications in oncology, neurology, and cardiology. However, while PET imagi...

see more →

Guidelines  93 results

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Journal of Clinical Oncology : Official Journal of the Am... Daly ME, Singh N et. al.

Dec 23rd, 2021 - To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, communit...

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Ganti AKP, Loo BW et. al.

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

Updated USPSTF screening guidelines may reduce lung cancer deaths.
The Journal of Family Practice; Marshall RC, Tiglao SM et. al.

Nov 25th, 2021 - By nearly doubling the number of patients eligible for screening, as many as 60,000 US lives may be saved-but concerns may limit acceptance.

Definition and assessment of high risk in patients considered for lobectomy for stage I...
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

see more →

Drugs  199 results see all →

Clinicaltrials.gov  2,403 results

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

May 13th, 2022 - Background: EGFR tyrosine kinase inhibitors (TKI) have significantly improved the response rate (RR) and survival in patients with tumors harboring EGFR-sensitizing mutations. An invariable consequence of treatment with EGFR-TKIs is the developmen...

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

May 13th, 2022 - Background Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. Extrapulmonary small cell ...

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer

May 13th, 2022 - Lung cancer is the primary cause of cancer death worldwide regardless of gender or age group. Based on the most recent statistics for our country, every year about 9000 new cases of lung cancer are diagnosed. Lung cancer is the most common type of...

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

May 13th, 2022 - This is a Phase 1b, open-label, multi-center, dose-escalation and dose-expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic NSCLC with a...

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Di...

May 13th, 2022 - Participants may receive additional 17 cycles of pembrolizumab/vibostolimab (each cycle length = 21 days) for an additional 1 year of treatment as second course phase at investigator's discretion.

see more →

News  6,352 results

Nearly 234,000 Cancer Cases Predicted in Canada This Year

May 13th, 2022 - About 233,900 new cancer cases and 85,100 cancer deaths are predicted to occur in Canada in 2022, according to new research. The most commonly diagnosed cancer overall will be lung cancer, followed by breast cancer for women and prostate cancer fo...

Quitting Smoking Even After Lung Cancer Diagnosis Worth Doing

May 12th, 2022 - Patients who quit smoking at or around the time of a lung cancer diagnosis live longer than those who continue to smoke, concludes a new meta-analysis. "Smokers who quit smoking at or around lung cancer diagnosis have a 29% improvement in their ov...

New Class of Cancer Drugs Down, Not Out, After Roche Trial Setback: Analysts

May 12th, 2022 - LONDON (Reuters) - The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, anal...

Women With Lung Cancer Live Longer Than Men

May 11th, 2022 - The observation that women with lung cancer seem to live longer than men can be explained by known prognostic factors, a new study suggests. “In this first Australian prospective study of lung cancer survival comparing men and women, we found that...

Genomic Testing Challenges Persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

see more →

Patient Education  51 results see all →